Stifel Financial
RPRX icon

Stifel Financial’s Royalty Pharma RPRX Stock Holding History

Stifel Financial’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Sell
21,259
-2,139
-9% -$111K ﹤0.01% 2442
2026
Q1 		$1.12M Buy
23,398
+3,183
+16% +$139K ﹤0.01% 2385
2025
Q4 		$781K Buy
20,215
+387
+2% +$14.8K ﹤0.01% 2591
2025
Q3 		$700K Buy
19,828
+3,512
+22% +$127K ﹤0.01% 2603
2025
Q2 		$588K Sell
16,316
-2,630
-14% -$87.1K ﹤0.01% 2679
2025
Q1 		$590K Buy
18,946
+1,794
+10% +$56.9K ﹤0.01% 2584
2024
Q4 		$438K Sell
17,152
-2,200
-11% -$58.3K ﹤0.01% 2755
2024
Q3 		$547K Sell
19,352
-530
-3% -$14.7K ﹤0.01% 2626
2024
Q2 		$524K Buy
19,882
+12,095
+155% +$335K ﹤0.01% 2594
2024
Q1 		$236K Buy
+7,787
New +$230K ﹤0.01% 3027
2023
Q3 		– Sell
-9,692
Closed -$298K – 3389
2023
Q2 		$298K Buy
9,692
+3,464
+56% +$117K ﹤0.01% 2826
2023
Q1 		$224K Buy
+6,228
New +$231K ﹤0.01% 2982
2022
Q4 		– Sell
-56,268
Closed -$2.26M – 3369
2022
Q3 		$2.26M Buy
56,268
+3,019
+6% +$129K ﹤0.01% 1384
2022
Q2 		$2.24M Buy
53,249
+44,829
+532% +$1.84M ﹤0.01% 1427
2022
Q1 		$329K Sell
8,420
-3,621
-30% -$142K ﹤0.01% 2826
2021
Q4 		$480K Buy
12,041
+6,495
+117% +$252K ﹤0.01% 2609
2021
Q3 		$201K Buy
5,546
+225
+4% +$8.74K ﹤0.01% 3132
2021
Q2 		$218K Sell
5,321
-55
-1% -$2.34K ﹤0.01% 3100
2021
Q1 		$235K Buy
+5,376
New +$255K ﹤0.01% 2932

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stifel Financial's RPRX Position: Q2 2026 in Review

Stifel Financial reduced its Royalty Pharma (RPRX) stake by 9.1% in Q2 2026, selling an estimated $111K and leaving 21,259 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2442.

Stifel Financial first reported a position in RPRX in Q1 2021 and has held it in 19 quarters since. The position peaked at $2.26M in Q3 2022. 642 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Stifel Financial held 21,259 shares of Royalty Pharma worth $1.19M as of Q2 2026.
  • Stifel Financial sold 2,139 Royalty Pharma shares in Q2 2026, an estimated $111K.
  • Royalty Pharma made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #2442 holding.
  • Stifel Financial first reported a position in Royalty Pharma in Q1 2021 and has held it in 19 quarters since.
  • Stifel Financial's Royalty Pharma position peaked at $2.26M in Q3 2022.
  • 642 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.